Regimens Comparison for Breast Cancers of Positive Lymph Nodes
Conditions
Breast Cancer
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
positive lymph node
Study Type
Interventional
Study Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Epirubicin, CTX, Paclitaxel Type: Drug
Name: Epirubicin, Paclitaxel Type: Drug
Overall Status
Recruiting
Summary
To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast cancer patients with positive lymph nodes
Detailed Description
EC-T regimen: epirubicin 90mg/m2 day1, CTX 600mg/m2, day 1, 21 days per cycle *4cycle. followed by paclitaxel 175mg/m2,d1,21days per cycle, 4 cycle.

ET regimen: epirubicin 75mg/m2 day1,paclitaxel 175mg/m2,d2,21days per cycle, 6 cycle
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- patients with breast cancer after breast cancer surgery with positive lymph nodes age 18-70 years old

Exclusion Criteria:

- with other malignance disease
Location
Cancer Institute & Hospital. Chinese Academy of Medical Sciences
Beijing, China
Status: Recruiting
Contact: Peng Yuan, M.D. - 86-10-8778 8114 - yuanpeng01@hotmail.com
Start Date
May 2010
Completion Date
May 2020
Sponsors
Chinese Academy of Medical Sciences
Source
Chinese Academy of Medical Sciences
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page